StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
KMDABullishEarningsnews
High materiality9/10

Kamada Delivers Record H1 2026, Reaffirms Guidance and Secures $50M Plasma Deal

Aug 12, 2026, 7:11 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong top-line growth, cash generation, and a meaningful multi-year plasma deal reduce execution risk and support a higher multiple, though macro risks remain a consideration.

AI summary

What happened, with direct paths to the underlying reporting

Kamada posted record first-half 2026 revenue of $100.2M and Adjusted EBITDA of $25.7M, reaffirming its guidance of $200–$205M in revenue and $50–$53M in EBITDA for 2026. The company also announced a three-year, roughly $50M plasma-supply deal and ongoing growth initiatives in distribution and plasma collection, suggesting durable double-digit profitability and improved cash flow into 2H 2026.

  • H1 2026 revenue $100.2M, up 13% YoY. EBITDA $25.7M, up 14%.
  • Q2 2026 revenue $54.9M, up 23% YoY. Adj EBITDA $14.1M, up 29%.
  • Reaffirms 2026 guidance: $200–$205M revenue; $50–$53M Adj EBITDA.
  • First-time three-year plasma supply deal ~ $50M.
  • Operating cash flow $17.8M in H1 2026; cash & equivalents $70.1M at 6/30/2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event